Orlistat Teva

Orlistat, the active ingredient in Orlistat Teva, is a lipase inhibitor presented as a tablet for oral use. It reduces dietary fat absorption and is used to aid weight management in adults and adolescents with obesity or overweight conditions.

GNH USA supplies Orlistat Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orlistat is a lipase‑inhibiting agent indicated for conditions related to excess body weight.

- Obesity: supports weight loss when combined with a reduced‑calorie, low‑fat diet. - Overweight adults: helps maintain weight loss achieved through diet and lifestyle changes. - Overweight adolescents (≥12 years): assists in weight reduction when used with dietary counseling.

Orlistat may cause gastrointestinal and nutritional adverse reactions.

Common Side Effects: - Oily spotting on underwear or clothing. - Increased flatulence with discharge. - Fecal urgency or incontinence. - Abdominal cramping or pain. - Frequent, oily or loose stools. - Reduced absorption of fat‑soluble vitamins.

Serious or Rare Side Effects: - Severe abdominal pain. - Acute liver injury. - Pancreatitis. - Allergic reactions such as rash, itching, or swelling. - Vitamin K deficiency leading to bleeding disorders. - Kidney stones.

Before initiating therapy, clinicians should evaluate patient suitability and counsel on diet.

- BMI assessment: confirm obesity or overweight status before prescribing. - Low‑fat diet: advise patients to limit dietary fat to ≤30 g per meal. - Vitamin monitoring: consider supplementation of vitamins A, D, E, K and monitor levels. - Contraindications: avoid use in patients with chronic malabsorption syndromes or cholestasis. - Pregnancy and lactation: not recommended during pregnancy or while breastfeeding. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Orlistat can affect the absorption of several concomitant medications.

Major Interactions (Avoid): - Cyclosporine: reduced systemic exposure may compromise immunosuppression. - Levothyroxine: decreased absorption can lead to sub‑therapeutic thyroid levels. - Warfarin: altered vitamin K absorption may increase anticoagulant effect.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy; advise additional non‑hormonal contraception. - Anticonvulsants (e.g., carbamazepine): possible decreased absorption; monitor seizure control. - Fat‑soluble vitamin supplements: timing should be separated by at least 2 hours to avoid reduced uptake.